AI주식인사이트AI Stock Insight
B

텔콘RF제약

200230KOSDAQ의약품 제조업

55.4 / 100

Reference Date: 2026-06-10

Financial Score24.0 / 40
News Sentiment14.4 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 38.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Telcon RF Pharmaceuticals primarily manufactures connectors and cable assemblies for wireless communication equipment, expanding into optical solutions and 5G FTTA (Fiber-To-The-Antenna) technology to strengthen its global market position. In the pharmaceutical and biotech sector, the company produces various dosage forms using KGMP-certified facilities and invests in new drug development.

Number of Employees

133people

Average Salary

55.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 11.934.0Point
PBR
0.24Industry Average 0.897.0Point

Half of industry avg (excellent)

ROE
-11.91Industry Average 4.010.0Point

Well below industry avg

Debt Ratio
1.46Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲9.1% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲505.6% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -8.4% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 1Negative 1Average Sentiment Score 57.5

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 360Won52-week high 3,80052-week low 360
1-month return0.0Point

1m -38.14% (strong drop)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0
  • Neutral감자완료2026-06-09
  • Neutral주권매매거래정지 (주식의 병합, 분할 등 전자등록 변경, 말소)2026-05-29
  • Neutral주요사항보고서(자기전환사채만기전취득결정)2026-05-27
  • Neutral임시주주총회결과2026-05-21
  • Neutral분기보고서 (2026.03)2026-05-15